COR2ED - Hematology Medical Conversation

COR2ED Medical Education

Join hematology medical experts as they discuss their approaches to hemato-oncology and hemostasis. The conversations explore scientific data, treatment landscapes, and patient experiences of various bleeding disorders and blood cancers incl. lymphoma, myeloma, hemophilia, von Willebrand disease and thrombosis. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com

  1. 05/01/2024

    Thrombophilia Screening: Best Practices and Who Should be Tested?

    What does thrombophilia testing mean for patients or their families? Do you know when and who to test for thrombophilia? In this podcast, experts Prof. Saskia Middeldorp and Prof. Jean Connors explore the diagnostic challenges for thrombophilia and which patients can benefit most from screening. In specific situations, testing can be crucial, but not always. Before testing, it is important to understand whether testing is needed and consider how it will provide support for decision making. ASH guidelines may be helpful. The experts discuss how these recommendations should be applied in general practice, as some caution is recommended.    Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/hemostasis-connect/programmes/thrombophilia-testing-part2/   Or go to the video on YouTube: https://youtu.be/uvXTtZHdT1k   Want to find out more? Listen to the other episode in the series:     Episode 1- Thrombophilia: Clinical overview and impact on patients  https://youtu.be/vy6r3JJLkG8?si=wXro9w7XYV6XS66U   https://cor2ed.com/hemostasis-connect/programmes/thrombophilia-part1/    The medical experts in this podcast express their own views, not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Pentapharm    This educational podcast is developed by cor2ed.com

    28 min
  2. 02/01/2024

    Thrombophilia: Clinical overview and impact on patients

    Thrombophilia: Clinical overview and impact on patients What do you know about thrombophilia? Is it acquired or inherited, and what is the impact on patients? This is the first in a 2-part podcast series focusing on Thrombophilia. In this episode, you will hear from Prof. Cedric Hermans, who is the Head of the division of Hematology, the Hemostasis and Thrombosis Unit and Hemophilia center of the Saint-Luc University hospital in Brussels, Belgium, and Prof. Sabine Eichinger, who is the Head of the Coagulation Clinic at the Medical University of Vienna, Austria. The experts discuss the main causes and symptoms of thrombophilia and the potential implications for the patient. They share their knowledge on the differences between acquired or inherited thrombophilia and discuss which specific patients can benefit from screening to prevent overtreatment or undertreatment.  Prefer to watch as well as listen? Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/hemostasis-connect/programmes/thrombophilia-podcast-series-part-1/ Or go to the video on YouTube: https://youtu.be/vy6r3JJLkG8 The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Pentapharm. This educational podcast is developed by cor2ed.com.

    27 min
  3. 12/07/2023

    Gene therapy and gene-modified cell therapy in rare diseases

    Gene therapy and gene-modified cell therapies have a great potential for rare diseases to either help patients to cure their disease or improve their lives. Did you know that gene therapy will probably become a major treatment option for many rare diseases in the near future? Listen as expert hematologists delve into this topic and take hemophilia as a practical example. Join Prof. Cédric Hermans (Head of the Division of Haematology, the Hemostasis and Thrombosis Unit and the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium) and Prof. Miguel Escobar (Professor of Medicine and Pediatrics, University of Texas Health Science Center at Houston-McGovern Medical School and University of Texas M.D. Anderson Cancer Center Medical Director, Gulf States Hemophilia & Thrombophilia Center Houston, USA) as they engage in a conversation about the potential of gene and gene-modified cell therapies in rare diseases, and how early gene therapies have been implemented as a treatment approach for rare diseases, such as leber congenital amaurosis, spinal muscular atrophy, beta-thalassemia, adrenoleukodystrophy, and hemophilia. The experts explore hemophilia as an example of how gene therapy has become a reality within rare diseases. They discuss why we need gene therapy for rare disease, what gene therapy and gene modified cell therapy is, and how this has become a reality in hemophilia, and look to the future of gene therapy for rare diseases. Finally they reflect on the importance of a multidisciplinary approach. - Access information on the programme, the clinical takeaways, the flashcard and the transcript here https://cor2ed.com/hemostasis-connect/programmes/gene-therapy-rare-diseases/ Find out about the experts Prof Cedric Hermans and Prof. Miguel Escobar.  The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from The American Society of Gene + Cell Therapy and Pfizer.

    28 min

About

Join hematology medical experts as they discuss their approaches to hemato-oncology and hemostasis. The conversations explore scientific data, treatment landscapes, and patient experiences of various bleeding disorders and blood cancers incl. lymphoma, myeloma, hemophilia, von Willebrand disease and thrombosis. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com